ONO 7268MX2

Drug Profile

ONO 7268MX2

Alternative Names: ONO7268MX2; Peptide-based cancer vaccine - OncoTherapy Science/Ono Pharmaceutical

Latest Information Update: 28 Mar 2016

Price : $50

At a glance

  • Originator OncoTherapy Science
  • Developer Immunovaccine; OncoTherapy Science; Ono Pharmaceutical
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma
  • Research Cancer

Most Recent Events

  • 28 Mar 2016 Phase-I development is ongoing in Japan
  • 13 May 2014 Phase-I clinical trials in Hepatocellular carcinoma in Japan (SC)
  • 12 Dec 2013 Ono Pharmaceutical submits an application for a phase I clinical trial of ONO 7268MX2 in Hepatocellular carcinoma in Japan .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top